Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03681535 · ClinicalTrials.gov registry record · NA
Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma
A NA study of Diffuse Large B Cell Lymphoma, sponsored by Duke University.
- Active
- Registry status
- NA
- Development phase
- 241
- Enrollment target
- 12
- Study locations
NCT03681535: Active NA study of Diffuse Large B Cell Lymphoma, sponsored by Duke University.
NCT03681535 is a NA study of Diffuse Large B Cell Lymphoma that is active but no longer recruiting, run by Duke University. The registered enrollment target is 241 participants, above the 217-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (11% higher). The trial reports 12 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03681535, a NA study of Diffuse Large B Cell Lymphoma, is active but no longer recruiting, sponsored by Duke University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 241 participants
- Enrollment target
- 12
- Study locations
Study Summary
This phase II study will evaluate whether a reduction in radiation dose and field size will maintain a high rate of local control while minimizing the risk of acute and late toxicity . Hypothesis: The radiation dose and treatment volume can be safely reduced from 30 Gy to 20 Gy while maintaining high rates of local control in patients who had a negative PET-CT scan following rituximab - containing chemotherapy.
Primary Outcome
Local control rate defined as the proportion of participants with absence of disease recurrence within the radiation therapy field as measured by standard of care imaging obtained per the National Comprehensive Cancer Network guidelines
Conditions Studied
Interventions
- RADIATION Radiation Therapy
Study Locations (12)
Other
- University Hospital Motol - Prague
- University of Torino - Torino
- Juntendo University - Tokyo
- National Cancer Center of Singapore - Singapore
- Yonsei University Health System - Seoul
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
- Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital - Weymouth
Missouri
- Washington University School of Medicine - St Louis
New York
- University of Rochester James P. Wilmot Cancer Institute - Rochester
North Carolina
- Duke University Medical Center - Durham
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 241 participants |
| Start Date | 2019-02-13 |
| Est. Completion | 2028-07 |
| Phase | NA |
What the registry record for NCT03681535 still lists
NCT03681535 is an interventional study that assigns participants to a tested intervention. The registered 241 participants enrollment target is mid-sized for trials with a published cap, above the 217-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (11% higher).
The record links to 1 condition, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Radiation Therapy is the first listed.
NCT03681535 lists 12 locations in 6 states (Other, Massachusetts, Missouri).
Frequently Asked Questions
What is clinical trial NCT03681535 about?
NCT03681535 is a clinical study titled "Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma". This phase II study will evaluate whether a reduction in radiation dose and field size will maintain a high rate of local control while minimizing the risk of acute and late toxicity . Hypothesis: The radiation dose and treatment volume can be safely reduced from 30 Gy to 20 Gy while maintaining hi...
What is the current status of trial NCT03681535?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 241 participants. The study started on 2019-02-13. Estimated completion is 2028-07.
What conditions does trial NCT03681535 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma.
What interventions are being tested in trial NCT03681535?
The interventions under investigation include: Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT03681535?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03681535 being conducted?
This trial has 12 study locations across Massachusetts, Missouri, New York, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03681535's enrollment target sits among peer trials
241 25th of 114 higher than 90 of 114 other Diffuse Large B Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diffuse Large B Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
RECRUITING · NA
-
Hyperfractionated Dual Equivalent Fractionated Radiation Therapy
RECRUITING · NA
-
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency
ACTIVE NOT RECRUITING · NA
-
Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma
ACTIVE NOT RECRUITING · NA
-
Use of a Patient Preferences Shared Decision-Making Encounter Tool in Clinical Practice for Patients With DLBCL and FL
COMPLETED · NA
-
Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01189786 · 241 participants · NA
Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection
- NCT05050383 · 241 participants · NA
DISE: Phenotyping Obstruction Patterns
- NCT05683418 · 241 participants · Phase 1
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors
- NCT07213791 · 241 participants · Phase 1
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI